The city-based PNB Vesper Life Sciences has successfully completed phase 2 clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to treat the coronavirus infection and said it will soon move the government for deploying the drug for emergency use.
The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support.
The company on Monday said the clinical trial was initiated in November at BJ Government Medical College and Sassoon General Hospital in Pune, and Victoria Medical College and Research Institute in Bengaluru on 40 patients.
